The Entheos Foundation is pleased to announce a sister project: Trypt.am! Trypt.am is a database of psychedelic clinical trials. It contains data from 4 international databases segmented by 10 popular psychedelics: LSD, DMT, Psilocybin, Ketamine, MDMA, Salvinorin A, Ibogaine, Mescaline, Ayahuasca, and Muscimol. These trials can be can be segmented further by country, condition (such as PTSD, depression, pain) and time of last update. It currently holds records of over 1200 clinical trials from all over the world collecting public data as far back as the year 2000.
This project was started near the start of the COVID-19 crisis during April 2020 and we are proud to release the beta version during the official launch of the Entheos Foundation.
The name, Trypt.am, is domain hack of Tryptamine, which is a common base for many psychedelics such as psilocybin and lysergic acid diethylamide.
What Trypt.am data tell us about New Zealand?
New Zealand does have an established niche in the current psychedelic renaissance. Here are statistics that are gleaned off Trypt.am‘s data since 2000:
- There are currently 25 historical, present, and future psychedelic clinical trials from New Zealand.
- While that number may seem small, New Zealand, is tied for 10th place in the number of psychedelic trials conducted since this data was collected with Turkey behind the United Kingdom (27 trials), Israel (29), Switzerland (39), France (56), Egypt (56), Canada (59), Australia (61), Netherlands (63), and the United States (487)
- New Zealand, in particular, has the majority of clinical trials for the novel drug ibogainel a psychedelic drug that is well known for its ability to heal severe addictions such as opioid dependence and withdrawal.
- Other psychedelics that are (or have been) studied in New Zealand include MDMA, LSD, and ketamine.
- Conditions for the New Zealand trials have included depression, anxiety, post traumatic stress disorder, anaesthesia, sedation, alcohol dependence, opioid dependence, opioid withdrawal, tinnitus, spider phobia, and pain.
Please note that information is subject to change pending data updates.
What does Trypt.am tell us about psychedelic clinical trials?
- Since 2010, psychedelic clinical trials have grown a whopping 220%.
- Ketamine accounts for 85% of the total psychedelic trials since the year 2000.
- Psilocybin and MDMA trials increased in the past few years.
- While LSD is the most popular psychedelic search on Google trends, it has not receive as many clinical trials as psilocybin, MDMA or ketamine.
- Pain is the top condition treated by psychedelics, however, Ketamine is a common anesthetic.
- Not far behind Pain is depression, which features a wide range of psychedelics including LSD, MDMA, Ketamine, Psilocybin and Ayahuasca.
- Currently, nearly halfway through the year of 2020, there are 109 psychedelic clinical trials either starting or scheduled. It is uncertain what effects the Covid-19 crisis will have on the trials but it is likely that there will be dip in all types of clinical trials in 2020 and, possibly, through 2021.
We are looking for volunteers for Trypt.am!
What does the future hold for this project? We would like to open source Trypt.am, and look for volunteers who can maintain the project. As this is a New Zealand project, we would like to give preference to New Zealanders who are interested. However, anyone with appropriate skills and passion for this subject may apply.
In particular, we are looking for a person(s) with the following skills.
- PHP Programmer (version 7+)
- Knowledge of JSON and XML
- Knowledge of Nginx and directives
- Ubuntu Server 18.04
- Github Experience
Although it is currently stable, there is still much to do for this project. Some of the goals include:
Add additional databases. Trypt.am currently uses data from the United States & Global (clinicaltrials.gov), Australia & New Zealand (anzctr.org.au), Europe (clinicaltrialsregister.eu), and the Netherlands (trialregisther.nl). For a complete list see:
Update databases. Automate data where possible, and regularly import manual databases. Unfortunately, while many of the databases are publicly available, many are not publicly available. For instance, the data from the US and Europe databases are automatically updated while data from Australia and New Zealand. In addition, both the ANZCTR and the WHO have communicated with us that will intend to have live feeds once the covid crisis subsides.
Work with multiple groups and stakeholders: This includes members of the Entheos Trust, NZ psychedelic community and international organisations (like World Health Organisation) .
If you are interested in volunteering for this project please email your CV and let us know why you would be interested in this project. Send your info with the subject Trypt.am to info (at) entheos.org.nz